Search results
Results from the WOW.Com Content Network
Novartis made a settlement of $422.5 million, including a $185 million criminal fine and forfeiture for the off-label promotion of the anti-epilepsy drug Trileptal. [29] Trileptal was approved by the FDA to treat partial seizures, but was allegedly promoted to treat pain and some psychiatric conditions.
Hydroxycut is a brand of dietary supplements that is marketed as a weight loss aid. Hydroxycut was originally developed and manufactured by MuscleTech Research and Development; MuscleTech was sold to Iovate Health Sciences in 2003–2004 and declared bankruptcy in 2005; Iovate continues to use MuscleTech as a brand to market Hydroxycut.
The following is a list of the 20 largest settlements reached between the United States Department of Justice and pharmaceutical companies from 2001 to 2013, ordered by the size of the total settlement. The settlement amount includes both the civil (False Claims Act) settlement and criminal fine.
The heavily marketed diet product line Hydroxycut has been blamed in the death of at least one person and for nearly two dozen serious ailments, prompting the U.S. Food and Drug Administration to ...
Total settlement: $60 million. Deadline to file claim: May 18, 2023. Requirements: Must have been an unlimited data customer between Oct. 1, 2011 and June 30, 2015.
Eli Lilly & Co., the Fortune 500 pharma firm that manufactures weight-loss injection Zepbound (tirzepatide), has a comparable oral medication in the works that could be approved by the FDA as ...
MuscleTech is a brand of dietary supplements, marketed by Iovate Health Sciences Inc., which includes Hydroxycut. It was owned by Canadian company Kerr Holdings which was acquired by the Xiwang Foodstuffs Company, a Chinese company, for $584 million in 2016.
When will court approve settlement? A final approval hearing will be held on December 16 at 9:30 a.m. Pacific time via teleconference, according to the settlement website. The court will hear ...